Evidence map›Paper›PMID 42195374›Full record

ArticleLife (Basel, Switzerland)2026

Blood Pressure Changes After Oral 5-Aminolevulinic Acid Hydrochloride Administered 4-8 h Before TURBT: An Additional Analysis of a Phase III Study (SPP2C102).

Hideo Fukuhara, Makito Miyake, Keita Kobayashi, Atsushi Ikeda, Kent Kanao, Yoshinobu Komai, Ryo Fujiwara, Yusuke Sato, Rikiya Taoka, Keiji Inoue and 2 more

Abstract read
In one paragraph

Article in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Hideo FukuharaDepartment of Urology, Kochi Medical School Hospital, Nankoku 783-8505, Japan.
Makito MiyakeDepartment of Urology, Nara Medical University Hospital, Kashihara 634-8522, Japan.ORCID 0000-0001-9503-7356
Keita KobayashiDepartment of Urology, Yamaguchi University Hospital, Yamaguchi 755-8505, Japan.
Atsushi IkedaDepartment of Urology, University of Tsukuba Hospital, Tsukuba 305-8576, Japan.ORCID 0000-0003-0934-5470
Kent KanaoDepartment of Uro-Oncology, Saitama Medical University International Medicine Center, Hidaka 350-1298, Japan.
Yoshinobu KomaiDepartment of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan.
Ryo FujiwaraDepartment of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan.ORCID 0000-0001-6566-1430
Yusuke SatoDepartment of Urology, The University of Tokyo Hospital, Tokyo 113-8655, Japan.
Rikiya TaokaDepartment of Urology, Kagawa University Hospital, Miki 761-0793, Japan.
Keiji InoueCenter for Photodynamic Medicine, Kochi Medical School, Kochi University, Nankoku 783-8505, Japan.
Kiyohide FujimotoDepartment of Urology, Nara Medical University Hospital, Kashihara 634-8522, Japan.ORCID 0000-0003-1507-2464
Mototsugu OyaDepartment of Urology, Keio University Hospital, Tokyo 160-8582, Japan.

Funding

SBI Pharmaceuticals (Japan) none
6 · The paper itself

Abstract

This study evaluated changes in blood pressure and hypotension-related adverse drug reactions (ADRs) following oral administration of 5-aminolevulinic acid hydrochloride (5-ALA) in patients undergoing transurethral resection of bladder tumor (TURBT). Photodynamic diagnosis under blue light has demonstrated superior sensitivity compared with that of white light when 5-ALA is administered 4 to 8 h before TURBT (95.3% vs. 61.1%,

Indexed as

5-aminolevulinic acidhypotensionnon-muscle invasive bladder cancerphotodynamic diagnosistransurethral resection of bladder tumor

Identifiers

PMID42195374
PMCPMC13209026

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.